David Dornan brings more than two decades of experience in oncology drug discovery and development, with deep expertise in antibody-drug conjugates (ADCs) and other targeted cancer therapies. His research has focused on diverse therapeutic modalities that target cancer vulnerabilities, modulate the immune system and deliver cytotoxic payloads to cancer cells via ADCs. Prior to Aadi, … Continue reading David Dornan, PhD